Clinical trial NCT05487651: Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies
Official title: Allogeneic Natural Killer T-Cells Expressing CD19 Specific Chimeric Antigen Receptor and Interleukin-15 in Relapsed or Refractory B-Cell Malignancies 2
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: NHL, Relapsed, Adult
B-cell Lymphoma
B-cell Leukemia
DLBCL - Diffuse Large B Cell Lymphoma
ALL, Adult B Cell
ALL, Childhood
CLL/SLL
Lead sponsor: Athenex, Inc.
Sponsor class: INDUSTRY
First posted: 2022-08-04
Enrollment: 36
Sex: ALL
Minimum age (years): 3
Maximum age (years): 75
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Phase 1 dose escalation
Primary purpose: TREATMENT

Brief summary: This study is a multi-center study to evaluate the safety of KUR-502 in subjects with refractory/relapsed B-cell NHL or leukemia (ALL or CLL).

Detailed description: KUR-502 will be manufactured from leukapheresis products from healthy donors. Subjects will be enrolled into 2 parallel cohorts (Cohort A \[non-ALL\] and Cohort B \[ALL\]). Each cohort will undergo dose escalation independently.

Three (3) dose levels will be evaluated in the ANCHOR and ANCHOR2 studies combined (1×107/m2, 3×107/m2, 1×108/m2). Dose levels are defined based on the number of transduced KUR-502 cells. Body surface area (BSA) will be capped at 2.4 m2. Subjects will receive \<1×104 allogeneic T cells/kg at any dose level.

The MTD will be determined once dose escalation is completed, and all subjects are evaluable for DLT. If there is no DLT that determines an MTD, a maximum dose level will be declared. Dose escalation will stop when 6 subjects have been treated at the MTD or highest dose level.

Eligibility criteria: INCLUSION CRITERIA

Subjects must meet all of the following criteria to be included in this study:

1. Signed written informed consent.
2. Diagnosis of CD19+ B-cell lymphoma or leukemia (ALL or CLL).

   * Subjects who previously received CD19-directed therapy must have biopsy or flow cytometry-confirmed CD19+ tumor following the CD19-directed therapy; may be performed by local laboratory.
3. The disease is:

   Cohort A (non-ALL subjects):
   * Relapsed or refractory after ≥2 lines of therapy, including a CD20 antibody, if an indolent lymphoma.
   * Relapsed or refractory after ≥2 lines of therapy, including ibrutinib and venetoclax, if CLL.
   * Relapsed or refractory after ≥2 lines of therapy, including a CD20 antibody and an anthracycline, and the subject is ineligible for autologous stem cell transplantation, if an aggressive or highly aggressive lymphoma.
   * Ineligibility for autologous stem cell transplantation includes non-responsive disease after salvage therapy and failure to mobilize stem cells for transplant.

   Cohort B (ALL subjects):
   * Relapsed or refractory after ≥2 lines of therapy.
4. Measurable disease by current criteria (Lugano criteria for lymphomas, IWG criteria for CLL, and detectable disease for ALL).
5. Age 3 to 75 years; subjects \<18 years old will not be enrolled as the first subject on any dose level.
6. BSA ≤2.4 m2.
7. Bilirubin \<2 times the upper limit of normal (ULN) (3 times if the subject has Gilbert syndrome).
8. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \<5 times ULN.
9. Estimated glomerular filtration rate (GFR) ≥50 mL/min.
10. Pulse oximetry ≥90% on room air.
11. Karnofsky or Lansky score ≥70.
12. Recovered from the acute toxic effects of all prior chemotherapy based on the enrolling physician's assessment (if some effects of chemotherapy are expected to last long term, for example, residual neuropathy, anemia, or alopecia, subject is eligible if meets other eligibility criteria).
13. Life expectancy \>12 weeks.

Exclusion Criteria:

Subjects who meet any of the following criteria will be excluded from this study:

1. Females who are breastfeeding or pregnant at Screening (as documented by a positive urine or serum pregnancy test; may be performed by local laboratory).
2. Females of childbearing potential who:

   * Had unprotected sexual intercourse within 30 days before study entry and who do not agree to use a highly effective method of contraception (eg, total abstinence, an intrauterine device, a double-barrier method \[such as condom plus diaphragm with spermicide\], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) through the Day 365 visit or for 30 days after study drug discontinuation.
   * Are currently abstinent, and do not agree to use a double-barrier method (as described above) or refrain from sexual activity through the Day 365 visit or for 30 days after study drug discontinuation.
   * Are using hormonal contraceptives but are not on a stable dose of the same hormonal contraceptive product for at least 4 weeks before dosing and who do not agree to use the same contraceptive through the Day 365 visit or for 30 days after study drug discontinuation.
3. Males who have not had a successful vasectomy (confirmed azoospermia) or they and their female partners do not meet the criteria above (ie, not of childbearing potential or practicing highly effective contraception through the Day 365 visit or for 30 days after study drug discontinuation). No sperm donation is allowed through the Day 365 visit or for 30 days after study drug discontinuation.
4. Currently receiving any investigational agents or received any cellular therapies within the previous 6 weeks prior to the KUR-502 infusion.
5. History of Grade 2 to 4 GvHD.
6. History of hypersensitivity reactions to murine protein-containing products.
7. Active infection with human immunodeficiency virus (HIV) or human T cell lymphotropic virus (HTLV).
8. Active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).
9. Uncontrolled active bacterial, fungal, or other viral infection.

Primary outcomes:
measure: Dose limiting toxicity (DLT) rate and grade of single dose of Kur-502
timeFrame: 4 weeks post T cell infusion
Secondary outcomes:
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: University of California, San Francisco
state: California
city: Portland
country: United States
facility: OHSU - Knight Cancer Center
state: Oregon
city: Houston
country: United States
facility: Baylor College of Medicine
state: Texas
Study officials:
affiliation: Baylor College of Medicine
name: Carlos Ramos, MD
role: PRINCIPAL_INVESTIGATOR
References: